Monoclonal antibodies for chronic pain: A practical review of mechanisms and clinical applications
Yeh J. -., Akinci A., Al S. M., Chang M. H., Danilov A. B., Guillen R., Johnson K. W., Kim Y. -., El-Shafei A. A., Skljarevski V., Dueñas H. J., Tassanawipas W.
Опубликовано: 2017
Тип ресурса: Обзор
DOI:10.1177/1744806917740233
Аннотация:
Context: Monoclonal antibodies are being investigated for chronic pain to overcome the shortcomings of current treatment options. Objective: To provide a practical overview of monoclonal antibodies in clinical development for use in chronic pain conditions, with a focus on mechanisms of action and relevance to specific classes. Methods: Qualitative review using a systematic strategy to search for randomized controlled trials, systematic and nonsystematic (narrative) reviews, observational studies, nonclinical studies, and case reports for inclusion. Studies were identified via relevant search terms using an electronic search of MEDLINE via PubMed (1990 to June 2017) in addition to hand-searching reference lists of retrieved systematic and nonsystematic reviews. Results: Monoclonal antibodies targeting nerve growth factor, calcitonin gene-related peptide pathways, various ion channels, tumor necrosis factor-α, and epidermal growth factor receptor are in different stages of development.
Ключевые слова:
Antibody therapy; biologics; central sensitization; chronic pain; monoclonal antibodies; peripheral sensitization
calcitonin gene related peptide; cetuximab; diclofenac; drug antibody; epidermal growth factor receptor; erlotinib; fasinumab; fulranumab; gefitinib; immunoglobulin class; mitogen activated protein kinase; monoclonal antibody; nerve growth factor; oxycodone; panitumumab; tanezumab; tumor necrosis factor; monoclonal antibody; adrenergic system; analgesia; bibliographic database; chronic pain; clinical development plan; diabetic neuropathy; drug mechanism; human; hyperalgesia; inflammatory pain; meta analysis (topic); migraine; nerve growth; neuropathic pain; nociception; nonhuman; osteoarthritis; patient compliance; phase 2 clinical trial (topic); priority journal; randomized controlled trial (topic); Review; signal transduction; systematic review (topic); animal; central nervous system sensitization; chronic pain; diabetic neuropathy; drug effect; neuralgia; treatment outcome; Animals; Antibodies, Monoclonal; Central Nervous System Sensitization; Chronic Pain; Diabetic Neuropathies; Hu
Язык текста: Английский
ISSN: 1744-8069
Yeh J. -. J.-F.
Akinci A.
Al S. M. Shaker M.
Chang M. H.
Danilov A. B. Andrej Borisovich 1962-
Guillen R.
Johnson K. W.
Kim Y. -. Y.-C.
El-Shafei A. A.
Skljarevski V.
Dueñas H. J.
Tassanawipas W.
Ьех Й. -. Й.-Ф.
Акинcи А.
Ал С. М. Шакер М.
Чанг М. Х.
Данилов А. Б. Андрей Борисович 1962-
Гуиллен Р.
Йохнсон К. W.
Ким Y. -. Y.-C.
Ел-Шафеи А. А.
Склйаревски В.
Дуеñас Х. Й.
Тассанаwипас W.
Monoclonal antibodies for chronic pain: A practical review of mechanisms and clinical applications
Текст визуальный непосредственный
Molecular Pain
BioMed Central Ltd.
Vol.13
2017
Обзор
Antibody therapy biologics central sensitization chronic pain monoclonal antibodies peripheral sensitization
calcitonin gene related peptide cetuximab diclofenac drug antibody epidermal growth factor receptor erlotinib fasinumab fulranumab gefitinib immunoglobulin class mitogen activated protein kinase monoclonal antibody nerve growth factor oxycodone panitumumab tanezumab tumor necrosis factor monoclonal antibody adrenergic system analgesia bibliographic database chronic pain clinical development plan diabetic neuropathy drug mechanism human hyperalgesia inflammatory pain meta analysis (topic) migraine nerve growth neuropathic pain nociception nonhuman osteoarthritis patient compliance phase 2 clinical trial (topic) priority journal randomized controlled trial (topic) Review signal transduction systematic review (topic) animal central nervous system sensitization chronic pain diabetic neuropathy drug effect neuralgia treatment outcome Animals Antibodies, Monoclonal Central Nervous System Sensitization Chronic Pain Diabetic Neuropathies Hu
Context: Monoclonal antibodies are being investigated for chronic pain to overcome the shortcomings of current treatment options. Objective: To provide a practical overview of monoclonal antibodies in clinical development for use in chronic pain conditions, with a focus on mechanisms of action and relevance to specific classes. Methods: Qualitative review using a systematic strategy to search for randomized controlled trials, systematic and nonsystematic (narrative) reviews, observational studies, nonclinical studies, and case reports for inclusion. Studies were identified via relevant search terms using an electronic search of MEDLINE via PubMed (1990 to June 2017) in addition to hand-searching reference lists of retrieved systematic and nonsystematic reviews. Results: Monoclonal antibodies targeting nerve growth factor, calcitonin gene-related peptide pathways, various ion channels, tumor necrosis factor-α, and epidermal growth factor receptor are in different stages of development.